News

Radionetics Oncology Enters Into Strategic Agreement With Lilly

Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against Novel Target for Adrenocortical Carcinoma

Radionetics Oncology Appoints Istvan Molnar, M.D. as Chief Medical Officer

Radionetics Oncology Appoints Umesh Gangadharmath, Ph.D. as Senior Vice President, Technical Operations

Radionetics Oncology Appoints Nishan de Silva, M.D. as Chief Executive Officer

Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology